Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian ...

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova to an untreated control group for the treatment of ...

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the ...

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in ...

A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of ...

New technologies and a proactive mindset are transforming how glaucoma is diagnosed and treated—and redefining what ...